<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873323</url>
  </required_header>
  <id_info>
    <org_study_id>TS142-209</org_study_id>
    <nct_id>NCT04873323</nct_id>
  </id_info>
  <brief_title>A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects</brief_title>
  <official_title>A Study to Evaluate the Effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate the effects on QT/QTc Interval of TS-142 in Healthy Adult&#xD;
      Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Actual">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTcF:QT-interval corrected by Fridericia corrections in Holter ECGs</measure>
    <time_frame>Up to 24 hours postdose during each period</time_frame>
    <description>Difference (ΔΔQTc) in change from baseline (ΔQTc) in QTc interval at each time point in each group compared with the placebo group</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS-142 therapeutic dose oral tablet (low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-142 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Description: TS-142 supratherapeutic dose oral tablet (high dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142</intervention_name>
    <description>Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period</description>
    <arm_group_label>TS-142 10 mg</arm_group_label>
    <arm_group_label>TS-142 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Single dose of moxifloxacin 400 mg in the morning under fasting in each period</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of TS-142 placebo in the morning under fasting in each period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese Males or females aged 20 years or older but less than 40 years at the time of&#xD;
             informed consent&#xD;
&#xD;
          -  those with a BMI of 18.5 in male (17.6 in female) or more and less than 25.0 and a&#xD;
             body weight of 40.0 kg or more at screening test&#xD;
&#xD;
          -  those whose pulse rate measured by standard 12-lead ECG is 50 beats/min or more but no&#xD;
             more than 90 beats/min at screening test and at the time before administration of&#xD;
             investigational drug in period 1&#xD;
&#xD;
          -  those who are judged eligible to participate in the study by the principal&#xD;
             investigator or sub-investigator based on the results of screening test and test&#xD;
             conducted before administration of investigational drug in period 1. However, if who&#xD;
             showed abnormal findings but not clinically significant, they can be enrolled in&#xD;
             clinical trials based on comprehensive consideration of medical viewpoints by the&#xD;
             principal investigator or subinvestigator.&#xD;
&#xD;
          -  those who are able to receive the explanation before participating in the study,&#xD;
             understand the content of the study, and provide written informed consent by the&#xD;
             subjects themselves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have any disease and are not considered healthy subjects based on the&#xD;
             medical judgment of the principal investigator or sub-investigator.&#xD;
&#xD;
          -  Subjects with a medical history considered inappropriate for participation in the&#xD;
             study, including respiratory, cardiovascular, gastrointestinal, hepatic, renal,&#xD;
             urological, endocrine, metabolic, hematological, immune, skin, neurological, and&#xD;
             psychiatric diseases.&#xD;
&#xD;
          -  Subjects with a history of drug allergy or food allergy.&#xD;
&#xD;
          -  Subjects with a history of hypersensitivity to moxifloxacin or other quinolone&#xD;
             antimicrobials&#xD;
&#xD;
          -  Subjects with risk factors or with a history of risk factors for aortic aneurysm,&#xD;
             aortic dissection (such as Marfan syndrome)&#xD;
&#xD;
          -  Subjects with significant allergic predisposition (such as asthma requiring medical&#xD;
             treatment)&#xD;
&#xD;
          -  Subjects with congenital disease, heart disease, or a history of heart disease&#xD;
&#xD;
          -  Subjects with risk factors or with a history of risk factors for torsade de pointes&#xD;
             (TdP) (heart failure, hypokalemia, family history of long QT syndrome, etc.)&#xD;
&#xD;
          -  Subjects with a history of unconscious seizures suspected of involving TdP.&#xD;
&#xD;
          -  Subjects with waveforms difficult to assess for QTc interval prolongation in standard&#xD;
             12-lead ECG at screening and the timing before administration of investigational&#xD;
             product in period 1 (drift, electromyography contamination, T-wave geometry, marked&#xD;
             sinus arrhythmia, frequent premature beats, etc.)&#xD;
&#xD;
          -  Subjects with QTcF(Fridericia correction method) of at least 450 msec in men and at&#xD;
             least 470 msec in women in standard-12-lead ECG at screening test and at the time&#xD;
             before administration of investigational product in period 1.&#xD;
&#xD;
          -  Subjects with suicidal ideation, suicide attempt on the Colombian Suicide Assessment&#xD;
             Scale (C-SSRS) on Day-1 or a history of suicide attempt within the previous 5 years.&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Direcoter</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Toshima-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

